STAT+: A preview of Neurocrine’s muscarinic drug readout

Off Adam's Biotech Scorecard, Biotech, biotechnology, Business, drug development, drug prices, Human Health, Life Sciences, Medicine, Pharma, research, Science and Research, STAT+

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Welcome back! I’ve been working from home almost this entire summer because of construction on the Red Line. I hate the MBTA. Boston readers know what I mean.

This week: “Muscarinics” are hot and Neurocrine Biosciences is the next biotech with a big study readout. I preview. Also, a few more words on the Cassava Sciences’ soap opera.

Continue to STAT+ to read the full story…

Read Original Article: STAT+: A preview of Neurocrine’s muscarinic drug readout »

About The Author